Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014 Mar;70(3):512–16. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0190962213012681.

Article  PubMed  Google Scholar 

Law RM, Gulliver WP. Psoriasis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach, 10e. New York, NY: McGraw-Hill Education; 2017. Available from: http://accesspharmacy.mhmedical.com/content.aspx?aid=1153075009.

Google Scholar 

Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013 Feb;133(2):377–85. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022202%D71536098X.

Article  CAS  PubMed  Google Scholar 

Alshamrani HM, Alsolami MA, Alshehri AM, Salman AK, Alharbi MW, Alzuhayri AJ, et al. Pattern of skin diseases in a university hospital in Jeddah, Saudi Arabia: age and sex distribution. Ann Saudi Med. 2019 Jan;39(1):22–28. Available from: http://www.annsaudimed.net/doi/10.5144/0256-4947.2019.22.

Article  PubMed  PubMed Central  Google Scholar 

Shelleh HH, Al-Hatiti HS. Pattern of skin diseases in a hospital in southwestern Saudi Arabia. Saudi Med J. 2004 Apr;25(4):507–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15083226.

PubMed  Google Scholar 

Agarwal PK. Pattern of skin diseases in Al-Jouf region. Ann Saudi Med. 1997 Jan;17(1):112–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17377479.

Article  CAS  PubMed  Google Scholar 

Alzeer F, AlOtair H, Aleisa A. Epidemiology and cutaneous manifestations of psoriasis in Saudi Arabia: a narrative review. Clin Cosmet Investig Dermatol. 2022 Feb;15:347–55. Available from: https://www.dovepress.com/epidemiology-and-cutaneous-manifestations-of-psoriasis-in-saudi-arabia-peer-reviewed-fulltext-article-CCID.

Article  PubMed  PubMed Central  Google Scholar 

Belasco J, Wei N. Psoriatic arthritis: what is happening at the joint? Rheumatol Ther. 2019 Sep;6(3):305–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31102105.

Article  PubMed  PubMed Central  Google Scholar 

Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005 Mar;64(Suppl 2):ii14–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15708927.

PubMed  PubMed Central  Google Scholar 

Daniel BS. The multiple comorbidities of psoriasis: the importance of a holistic approach. Aust J Gen Pract. 2020 Jul;49(7):433–37. Available from: https://www1.racgp.org.au/ajgp/2020/july/the-multiple-comorbidities-of-psoriasis.

Article  PubMed  Google Scholar 

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019 Jan;80(1):251–265.e19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29928910.

Article  PubMed  Google Scholar 

Gisondi P, Bellinato F, Maurelli M, Geat D, Zabotti A, McGonagle D, et al. Reducing the risk of developing psoriatic arthritis in patients with psoriasis. Psoriasis (Auckland NZ). 2022;12:213–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35975124.

Google Scholar 

Bedaiwi M, Al-Homood IA, El-Garf A, Uthman I, Sunna N, Nassier R, et al. Disease burden and treatment challenges of psoriatic arthritis in Africa and the Middle East. Rheumatol Int. 2019 Aug;39(8):1321–29. Available from: http://link.springer.com/10.1007/s00296-019-04319-3.

Article  PubMed  Google Scholar 

Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018 Dec;55(3):379–90. Available from: http://link.springer.com/10.1007/s12016-018-8702-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019 Sep;78(9):1167–78. Available from: http://ard.bmj.com/content/78/9/1167.abstract.

Article  CAS  PubMed  Google Scholar 

Galluzzo M, Talamonti M, De Simone C, D’Adamio S, Moretta G, Tambone S, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018 Jul;18(7):727–35. Available from: https://www.tandfonline.com/doi/full/10.1080/14712598.2018.1481503.

Article  CAS  PubMed  Google Scholar 

Wang EA, Suzuki E, Maverakis E, Adamopoulos IE. Targeting IL-17 in psoriatic arthritis. Eur J Rheumatol. 2017 Dec;4(4):272–77. Available from: https://eurjrheumatol.org//en/targeting-il-17-in-psoriatic-arthritis-133030.

Article  PubMed  PubMed Central  Google Scholar 

Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D’Angelo S, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021 May;80(5):582–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33334727.

Article  CAS  PubMed  Google Scholar 

Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015 Feb;75(3):329–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25648267.

Article  CAS  PubMed  Google Scholar 

Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29444376.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res (Hoboken). 2017 Mar;69(3):347–55. Available from: https://onlinelibrary.wiley.com/doi/10.1002/acr.23111.

Article  CAS  PubMed  Google Scholar 

Coates LC, Mease PJ, Gossec L, Kirkham B, Sherif B, Gaillez C, et al. Minimal disease activity among active psoriatic Arthritis patients treated with secukinumab: 2-year results from a multicenter, randomized, double-Blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529–35. Available from: https://onlinelibrary.wiley.com/doi/10.1002/acr.23537.

Article  CAS  PubMed  Google Scholar 

Ramonda R, Lorenzin M, Carriero A, Chimenti MS, Scarpa R, Marchesoni A, et al. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open. 2021 Feb;7(1):e001519. Available from: https://rmdopen.bmj.com/lookup/doi/10.1136/rmdopen-2020-001519.

Article  PubMed  PubMed Central  Google Scholar 

Thaçi D, Blauvelt A, Reich K, Tsai T-F, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015 Sep;73(3):400–09. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26092291.

Article  PubMed  Google Scholar 

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014 Jul;371(4):326–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25007392.

Article  PubMed  Google Scholar 

Blauvelt A, Reich K, Tsai T-F, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017 Jan;76(1):60–69.e9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27663079.

Article  CAS  PubMed  Google Scholar 

Korman NJ, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, et al. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. J Dermatolog Treat. 2017 Aug;28(5):384–89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27832717.

Article  CAS  PubMed  Google Scholar 

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401–07. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26866518.

Article  CAS  PubMed  Google Scholar 

Mease PJ, Landewé R, Rahman P, Tahir H, Singhal A, Boettcher E, et al. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open. 2021 Jul;7(2). Available from: http://www.ncbi.nlm.nih.gov/pubmed/34330846.

Albanghali MA. Prevalence of consanguineous marriage among Saudi Citizens of Albaha, a cross-sectional study. Int J Environ Res Public Health. 2023 Feb;20(4):3767. Available from: https://www.mdpi.com/1660-4601/20/4/3767.

Article  PubMed  PubMed Central  Google Scholar 

Megna M, Balato A, Napolitano M, Gallo L, Caso F, Costa L, et al. Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”. Clin Rheumatol. 2018 Jul;37(7):1739–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29644570.

Article  PubMed  Google Scholar 

Oguz Topal I, Baysak S, Altunay İK, Kara Polat A, Arıkan EE, Özkur E, et al. Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study. An Bras Dermatol. 2022;97(5):566–74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35843765.

Article  PubMed  PubMed Central  Google Scholar 

Galluzzo M, D’Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2020 Feb;20(2):173–82. Available from: https://www.tandfonline.com/doi/full/10.1080/14712598.2020.1708897.

Article  CAS